Business Context and Reporting Period
This Form 8-K was filed by AtriCure, Inc. on July 18, 2006. The report discloses the entry into a Material Definitive Agreement with The Cleveland Clinic, effective retroactively to June 6, 2005. The agreement concerns rights and obligations related to State of Ohio grants intended to establish the Atrial Fibrillation Innovation Center to develop treatments for atrial fibrillation.
Key Financial Metrics and Agreement Terms
The filing details specific financial commitments and inflows over a three-year period under the new agreement:
- Revenue/Inflows: AtriCure will receive up to approximately $0.9 million for personnel and materials.
- Capital Equipment: The Cleveland Clinic will acquire up to approximately $2.4 million in capital equipment for AtriCure's use.
- Operating Expenses: AtriCure is required to expend approximately $7.7 million for operating expenses.
- Capital Expenses: AtriCure is required to expend approximately $4.8 million for capital expenses at its facility.
The filing text does not provide clear values for the company's overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Intellectual Property
The agreement specifies the division of ownership for intellectual property developed during the performance of the agreement:
- AtriCure will own all intellectual property it develops alone.
- AtriCure will own certain jointly developed intellectual property.
- AtriCure will have the option to license certain intellectual property owned by The Cleveland Clinic that is developed under the agreement.
The company notes that the required expenditures represent ordinary course expenditures it would have otherwise anticipated making.
Outlook, Risks, and Termination
The agreement is set to terminate on December 6, 2008. However, both parties retain the right to terminate the agreement at any time by providing 30 days' prior written notice. The filing does not contain specific management guidance, outlook, or discussion of risks beyond the terms of this specific agreement.
Key Facts for Investor Verification
- Verify the total projected cash outflow of approximately $12.5 million ($7.7M operating + $4.8M capital) against the company's current liquidity position.
- Confirm the status of the State of Ohio grants referenced in the agreement.
- Review the full text of the Agreement (Exhibit 10.1) for specific definitions of "jointly developed" intellectual property and licensing terms.
- Assess the impact of the 30-day termination clause on the stability of the three-year project timeline.